中文   SEARCH
Home > Resources > MRI Imaging Platform
MRI Imaging Platform

MicroMRI-Bruker 9.4T/200mm

Equipment Type MicroMRI-Bruker 9.4T/200mm
Capabilities Small animal imaging
Status Active
Reserve time 9:00--18:00
Contact staff Fan Zhang
Application form PDF icon PDF
Email xiamen-cmitm@xmu.edu.cn

Performance

Equpided with 9.4 T high field strength, This NMR scancer have higher spatial, temporal and spectral resolution compared to clinical scanners.

The instrument has huge functions:

  1. Systemic anatomical imaging to provide the information about anatomical structures in whole body of  the test animal.

  2. T1 ,T2 Measurement and T2-Mapping to characterize tissue properties to differentiate between normal and cancerous tissue or to diagnose brain injuries.

  3. Contrast Agent imaging to give information e.g. about cerebral ischemia (cerebral infarcts), stenosis in vessels, flow rates, quantitative and qualitative heart analysis, intra-cranial tumors, and tumors in thoracal and abdominal organs.

  4. Diffusion Weighted Imaging (DWI) to assess tumor tissue ischemia, necrosis, or cellular lysis.

  5. Chemical Shift Imaging to examine the distribution of spectral components within the volume of  interest.

  6. Visualization of vessels in the brain, heart, liver, kidneys, spine, extremities, and more, proving valuable information about pathologies such as glioblastoma, inflammation, aneurysms, and congenital vascular abnormalities.

  7. Cardiac MR imaging to determine the anatomy and the dynamics of 3D heart structures (e.g. walls and cavities).

  8. Spectroscopy imaging and so on.

Main parameters of the instrument:

  • Magnetic field intensity:9.4 T
  • Transparent aperture diameter:300 mm
  • Stray magnetic field(5 gauss):+/- 3.3 m axial direction,+/- 2.3 m radial direction
  • Length :2.08 m
  • Diameter :1.706 m

Application

 

T2-weighted MR images and T2 transverse relaxivity (R2) of GO-IONP-PEG solutions at different iron concentrations

(a)                                            (b)

T2-weighted imaging of tumor (a) and Diffusion-weighted imaging (DWI-MRI) of tumor (b)

T2-weighted imaging of live before and after contrast agent injection

Frist Prev Page 1 of 0 Next Last